Design, synthesis and biological evaluation of PD-1 derived peptides as inhibitors of PD-1/PD-L1 complex formation for cancer therapy-Reference-Cited by-同舟云学术

Design, synthesis and biological evaluation of PD-1 derived peptides as inhibitors of PD-1/PD-L1 complex formation for cancer therapy

Published:2022-11 Issue: Volume:128 Page:106047
ISSN:0045-2068
Container-title:Bioorganic Chemistry
language:en
Short-container-title:Bioorganic Chemistry

Author:

Bojko Magdalena,Węgrzyn Katarzyna,Sikorska Emilia,Kocikowski Mikołaj,Parys Maciej,Battin Claire,Steinberger Peter,Kogut Małgorzata M.,Winnicki Michał,Sieradzan Adam K.,Spodzieja Marta,Rodziewicz-Motowidło Sylwia^ORCID

Funder

Polpharma Scientific Foundation

Publisher

Elsevier BV

Subject

Organic Chemistry,Drug Discovery,Molecular Biology,Biochemistry

Reference81 articles.

1. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade;Iwai;Proc. Natl. Acad. Sci. U. S. A.,2002

2. Pembrolizumab: First global approval;Poole;Drugs.,2014

3. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab;Topalian;J. Clin. Oncol.,2014

4. Beyond melanoma: inhibiting the PD-1/PD-L1 pathway in solid tumors;Gentzler;Immunotherapy.,2016

5. Cemiplimab: First Global Approval;Markham;Drugs.,2018

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Methods for monitoring protein-membrane binding. Comparison based on the interactions between amyloidogenic protein human cystatin C and phospholipid liposomes;International Journal of Biological Macromolecules;2024-10

2. In Search of Better Peptide-(Derived from PD-L2)-Based Immune Checkpoint Inhibitors;Biomolecules;2024-05-18

3. Peptide-based inhibitors targeting the PD-1/PD-L1 axis: potential immunotherapeutics for cancer;Translational Oncology;2024-04

4. Targeted therapy, immunotherapy, and small molecules and peptidomimetics as emerging immunoregulatory agents for melanoma;Cancer Letters;2024-04

5. Light-activated azobenzene peptide inhibitor of the PD-1/PD-L1 interaction;Chemical Communications;2024